A randomized, multicenter, open-label study to comparison of tenofovir monotherapy with entecavir-adefovir combination in suboptimal responder for lamivudine plus adefovir rescue therapy in chronic hepatitis B patients with YMDD mutation
Phase of Trial: Phase IV
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Tenofovir (Primary) ; Adefovir; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms TEAM
- 15 Nov 2016 Primary endpoint (Proportion of patients with complete virological response (HBV-DNA 20 IU/mL) at week 96) has been met.
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.